Drugs / EU-Humira
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03052322 Comparator | Jan 2017 → May 2018 | rheumatoid arthritis | Fresenius Kabi SwissBioSim GmbH | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EU-Humira | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03052322 ↗ |
| Route | Subcutaneous | “Participants received EU-Humira subcutaneously at dose of 40 mg every other week from Day 1 up to Week 48.” NCT03052322 ↗ |